
The weight-loss drug Zepbound provides more health benefits than dropping pounds and controlling diabetes, a new study shows. It also appears to help people with obesity manage their high blood pressure, results show. Patients taking Zepbound (tirzepatide) experienced a significant reduction in their systolic blood pressure, the top number in a blood pressure reading, according to a study published Feb. 5 in the journal Hypertension. Systolic blood pressure is a stronger predictor for heart-related death than the diastolic bottom number, researchers said in background notes. “Although tirzepatide has been studied as a weight-loss medication, the blood pressure reduction in our patients in this study was impressive,” said lead researcher Dr. James de Lemos, chair of cardiology at UT Southwestern Medical Center in Dallas. Tirzepatide works by mimicking two hormones in the body that stimulate insulin secretion and sensitivity after a person eats. The drug helps slow down digestion, reduce appetite and regulate blood sugar levels. For the study, 600 adults with obesity were assigned to take either a placebo or varying doses of tirzepatide, which is administered through injection. After 36 weeks, results showed that: Participants taking 5 mg of tirzepatide had an average systolic blood pressure reduction of 7.4 mm Hg People taking 10 mg had an average systolic blood pressure reduction of 10.6 mm Hg Participants taking 15 mg had an average systolic… read on > read on >